The hallmarks of castration-resistant prostate cancers

Cancer Treatment Reviews

Volumn 41, Issue 7, 2015, Pages 588-597

  Katsogiannou, Maria ^a,b,c,d   Ziouziou, Hajer ^a,b,c,d   Karaki, Sara ^a,b,c,d   Andrieu, Claudia ^a,b,c,d   Henry de Villeneuve, Marie ^a,b,c,d   Rocchi, Palma ^a,b,c,d  

^a AIX MARSEILLE UNIVERSITY   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d CNRS   (France)

Author keywords

Androgen receptor; Castration resistant mechanisms; Hallmarks; Prostate cancer

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; ANTIAPOPTOTIC PROTEIN DERIVATIVE; MICRORNA; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ANDROGEN DEPRIVATION THERAPY; ANDROGEN METABOLISM; CANCER GROWTH; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CHEMOSENSITIVITY; DISEASE ACTIVITY; DNA MODIFICATION; EPIGENETICS; EVIDENCE BASED MEDICINE; GENE CONTROL; GENE FUSION; HUMAN; NEUROSECRETORY CELL; NONHUMAN; PROTEIN EXPRESSION; PTEN GENE; REVIEW; TUMOR SUPPRESSOR GENE; DISEASE COURSE; MALE; QUALITY OF LIFE;

DISEASE PROGRESSION; HUMANS; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; QUALITY OF LIFE;

EID: 84937639205     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2015.05.003     Document Type: Review

References (167)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
3. Fusi A., Procopio G., Della Torre S., Ricotta R., Bianchini G., Salvioni R., et al. Treatment options in hormone-refractory metastatic prostate carcinoma. Tumori 2004, 90:535-546.
4. Galsky M.D., Small A.C., Tsao C.K., Oh W.K. Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes. CA Cancer J Clin 2012, 62:299-308.
5. Gundem G., Van Loo P., Kremeyer B., Alexandrov L.B., Tubio J.M., Papaemmanuil E., et al. The evolutionary history of lethal metastatic prostate cancer. Nature 2015, 520:353-357.
6. Suzman D.L., Antonarakis E.S. Castration-resistant prostate cancer: latest evidence and therapeutic implications. Ther Adv Med Oncol 2014, 6:167-179.
7. MacVicar G.R., Hussain M.H. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer. Curr Opin Oncol 2013, 25:252-260.
8. Geller J. Prolonging survival in metastatic prostate cancer: the case for adrenal androgens-overview and summary of therapeutic controversies in prostatic cancer. J Clin Endocrinol Metab 1995, 80:1074-1078.
9. Mohler J.L. Castration-recurrent prostate cancer is not androgen-independent. Adv Exp Med Biol 2008, 617:223-234.
10. Craft N., Chhor C., Tran C., Belldegrun A., DeKernion J., Witte O.N., et al. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res 1999, 59:5030-5036.
11. Debes J.D., Tindall D.J. The role of androgens and the androgen receptor in prostate cancer. Cancer Lett 2002, 187:1-7.
12. Devlin H.L., Mudryj M. Progression of prostate cancer: multiple pathways to androgen independence. Cancer Lett 2009, 274:177-186.
13. Feldman B.J., Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001, 1:34-45.
14. Lamont K.R., Tindall D.J. Minireview: alternative activation pathways for the androgen receptor in prostate cancer. Mol Endocrinol 2011, 25:897-907.
15. Saraon P., Jarvi K., Diamandis E.P. Molecular alterations during progression of prostate cancer to androgen independence. Clin Chem 2011, 57:1366-1375.
16. Rocchi P., Muracciole X., Fina F., Mulholland D.J., Karsenty G., Palmari J., et al. Molecular analysis integrating different pathways associated with androgen-independent progression in LuCaP 23.1 xenograft. Oncogene 2004, 23:9111-9119.
17. Wyatt A.W., Gleave M.E. Targeting the adaptive molecular landscape of castration-resistant prostate cancer. EMBO Mol Med 2015.
18. Arnold J.T., Isaacs J.T. Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocr Relat Cancer 2002, 9:61-73.
19. Pienta K.J., Bradley D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 2006, 12:1665-1671.
20. Bubendorf L., Kononen J., Koivisto P., Schraml P., Moch H., Gasser T.C., et al. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 1999, 59:803-806.
21. Edwards J., Krishna N.S., Witton C.J., Bartlett J.M. Gene amplifications associated with the development of hormone-resistant prostate cancer. Clin Cancer Res 2003, 9:5271-5281.
22. Scher H.I., Beer T.M., Higano C.S., Anand A., Taplin M.E., Efstathiou E., et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010, 375:1437-1446.
23. Schalken J., Fitzpatrick J.M. Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer. BJU Int 2015.
24. Holzbeierlein J., Lal P., LaTulippe E., Smith A., Satagopan J., Zhang L., et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004, 164:217-227.
25. Montgomery R.B., Mostaghel E.A., Vessella R., Hess D.L., Kalhorn T.F., Higano C.S., et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008, 68:4447-4454.
26. Dutt S.S., Gao A.C. Molecular mechanisms of castration-resistant prostate cancer progression. Future Oncol 2009, 5:1403-1413.
27. Makridakis N., Ross R.K., Pike M.C., Chang L., Stanczyk F.Z., Kolonel L.N., et al. A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase. Cancer Res 1997, 57:1020-1022.
28. Locke J.A., Guns E.S., Lubik A.A., Adomat H.H., Hendy S.C., Wood C.A., et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008, 68:6407-6415.
29. Mohler J.L. A role for the androgen-receptor in clinically localized and advanced prostate cancer. Best Pract Res Clin Endocrinol Metab 2008, 22:357-372.
30. Marcelli M., Ittmann M., Mariani S., Sutherland R., Nigam R., Murthy L., et al. Androgen receptor mutations in prostate cancer. Cancer Res 2000, 60:944-949.
31. Taplin M.E., Bubley G.J., Shuster T.D., Frantz M.E., Spooner A.E., Ogata G.K., et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995, 332:1393-1398.
32. Tilley W.D., Buchanan G., Hickey T.E., Bentel J.M. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 1996, 2:277-285.
33. Brooke G.N., Bevan C.L. The role of androgen receptor mutations in prostate cancer progression. Curr Genomics 2009, 10:18-25.
34. Culig Z., Hobisch A., Cronauer M.V., Radmayr C., Trapman J., Hittmair A., et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994, 54:5474-5478.
35. Taplin M.E. Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol 2007, 4:236-244.
36. Veldscholte J., Berrevoets C.A., Brinkmann A.O., Grootegoed J.A., Mulder E. Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry 1992, 31:2393-2399.
37. Zhao X.Y., Malloy P.J., Krishnan A.V., Swami S., Navone N.M., Peehl D.M., et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 2000, 6:703-706.
38. Bergerat J.P., Ceraline J. Pleiotropic functional properties of androgen receptor mutants in prostate cancer. Hum Mutat 2009, 30:145-157.
39. Culig Z., Klocker H., Bartsch G., Hobisch A. Androgen receptor mutations in carcinoma of the prostate: significance for endocrine therapy. Am J Pharmacogenomics 2001, 1:241-249.
40. Suzuki H., Sato N., Watabe Y., Masai M., Seino S., Shimazaki J. Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Mol Biol 1993, 46:759-765.
41. Taplin M.E., Bubley G.J., Ko Y.J., Small E.J., Upton M., Rajeshkumar B., et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 1999, 59:2511-2515.
42. Steinkamp M.P., O'Mahony O.A., Brogley M., Rehman H., Lapensee E.W., Dhanasekaran S., et al. Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res 2009, 69:4434-4442.
43. Black B.E., Vitto M.J., Gioeli D., Spencer A., Afshar N., Conaway M.R., et al. Transient, ligand-dependent arrest of the androgen receptor in subnuclear foci alters phosphorylation and coactivator interactions. Mol Endocrinol 2004, 18:834-850.
44. Chmelar R., Buchanan G., Need E.F., Tilley W., Greenberg N.M. Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int J Cancer 2007, 120:719-733.
45. Li W., Cavasotto C.N., Cardozo T., Ha S., Dang T., Taneja S.S., et al. Androgen receptor mutations identified in prostate cancer and androgen insensitivity syndrome display aberrant ART-27 coactivator function. Mol Endocrinol 2005, 19:2273-2282.
46. Ceraline J., Cruchant M.D., Erdmann E., Erbs P., Kurtz J.E., Duclos B., et al. Constitutive activation of the androgen receptor by a point mutation in the hinge region: a new mechanism for androgen-independent growth in prostate cancer. Int J Cancer 2004, 108:152-157.
47. Chan S.C., Li Y., Dehm S.M. Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal. J Biol Chem 2012, 287:19736-19749.
48. Guo Z., Yang X., Sun F., Jiang R., Linn D.E., Chen H., et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 2009, 69:2305-2313.
49. Marcias G., Erdmann E., Lapouge G., Siebert C., Barthelemy P., Duclos B., et al. Identification of novel truncated androgen receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory prostate cancer (PCa) cell line. Hum Mutat 2009, 31:74-80.
50. Hu R., Dunn T.A., Wei S., Isharwal S., Veltri R.W., Humphreys E., et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009, 69:16-22.
51. Sun S., Sprenger C.C., Vessella R.L., Haugk K., Soriano K., Mostaghel E.A., et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 2010, 120:2715-2730.
52. Hornberg E., Ylitalo E.B., Crnalic S., Antti H., Stattin P., Widmark A., et al. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS ONE 2011, 6:e19059.
53. Li Y., Chan S.C., Brand L.J., Hwang T.H., Silverstein K.A., Dehm S.M. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res 2013, 73:483-489.
54. Andersen R.J., Mawji N.R., Wang J., Wang G., Haile S., Myung J.K., et al. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 2010, 17:535-546.
55. Snoek R., Cheng H., Margiotti K., Wafa L.A., Wong C.A., Wong E.C., et al. In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. Clin Cancer Res 2009, 15:39-47.
56. Compagno D., Merle C., Morin A., Gilbert C., Mathieu J.R., Bozec A., et al. SIRNA-directed in vivo silencing of androgen receptor inhibits the growth of castration-resistant prostate carcinomas. PLoS ONE 2007, 2:e1006.
57. Manin M., Martinez A., Van Der Schueren B., Reynaert I., Jean C. Acquisition of androgen-mediated expression of mouse vas deferens protein (MVDP) gene in cultured epithelial cells and in vas deferens during postnatal development. J Androl 2000, 21:641-650.
58. Wu J.D., Haugk K., Woodke L., Nelson P., Coleman I., Plymate S.R. Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J Cell Biochem 2006, 99:392-401.
59. Edwards J., Bartlett J.M. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: Androgen-receptor cofactors and bypass pathways. BJU Int 2005, 95:1327-1335.
60. Lee S.O., Lou W., Hou M., de Miguel F., Gerber L., Gao A.C. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res 2003, 9:370-376.
61. Lee S.O., Lou W., Hou M., Onate S.A., Gao A.C. Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway. Oncogene 2003, 22:7981-7988.
62. Ueda T., Bruchovsky N., Sadar M.D. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem 2002, 277:7076-7085.
63. Lemmon M.A., Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010, 141:1117-1134.
64. Wen Y., Hu M.C., Makino K., Spohn B., Bartholomeusz G., Yan D.H., et al. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 2000, 60:6841-6845.
65. Manin M., Baron S., Goossens K., Beaudoin C., Jean C., Veyssiere G., et al. Androgen receptor expression is regulated by the phosphoinositide 3-kinase/Akt pathway in normal and tumoral epithelial cells. Biochem J 2002, 366:729-736.
66. Yeh S., Lin H.K., Kang H.Y., Thin T.H., Lin M.F., Chang C. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 1999, 96:5458-5463.
67. Gregory C.W., Fei X., Ponguta L.A., He B., Bill H.M., French F.S., et al. Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J Biol Chem 2004, 279:7119-7130.
68. Nadiminty N., Lou W., Sun M., Chen J., Yue J., Kung H.J., et al. Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells. Cancer Res 2010, 70:3309-3319.
69. Amato R.J., Wilding G., Bubley G., Loewy J., Haluska F., Gross M.E. Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer. Clin Genitourin Cancer 2012, 10:232-238.
70. Templeton A.J., Dutoit V., Cathomas R., Rothermundt C., Bartschi D., Droge C., et al. Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08). Eur Urol 2013, 64:150-158.
71. Kruczek K., Ratterman M., Tolzien K., Sulo S., Lestingi T.M., Nabhan C. A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naive castration-resistant prostate cancer. Br J Cancer 2013, 109:1711-1716.
72. Thomas C., Lamoureux F., Crafter C., Davies B.R., Beraldi E., Fazli L., et al. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo. Mol Cancer Ther 2013, 12:2342-2355.
73. Dehm S.M., Tindall D.J. Regulation of androgen receptor signaling in prostate cancer. Expert Rev Anticancer Ther 2005, 5:63-74.
74. Gregory C.W., He B., Johnson R.T., Ford O.H., Mohler J.L., French F.S., et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001, 61:4315-4319.
75. Halkidou K., Gnanapragasam V.J., Mehta P.B., Logan I.R., Brady M.E., Cook S., et al. Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene 2003, 22:2466-2477.
76. Heemers H.V., Tindall D.J. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 2007, 28:778-808.
77. Mestayer C., Blanchere M., Jaubert F., Dufour B., Mowszowicz I. Expression of androgen receptor coactivators in normal and cancer prostate tissues and cultured cell lines. Prostate 2003, 56:192-200.
78. Leotoing L., Meunier L., Manin M., Mauduit C., Decaussin M., Verrijdt G., et al. Influence of nucleophosmin/B23 on DNA binding and transcriptional activity of the androgen receptor in prostate cancer cell. Oncogene 2008, 27:2858-2867.
79. Beaudoin C., Maquaire S., Leotoing L., Allemand J., Lours-Calet C., Veyssiere G., et al. NPM: a new player in prostate cancer?. Med Sci (Paris) 2009, 25:19-21.
80. Munuganti R.S., Hassona M.D., Leblanc E., Frewin K., Singh K., Ma D., et al. Identification of a potent antiandrogen that targets the BF3 site of the androgen receptor and inhibits enzalutamide-resistant prostate cancer. Chem Biol 2014, 21:1476-1485.
81. Ravindranathan P., Lee T.K., Yang L., Centenera M.M., Butler L., Tilley W.D., et al. Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer. Nat Commun. 2013, 4:1923.
82. Qiu Y., Robinson D., Pretlow T.G., Kung H.J. Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. Proc Natl Acad Sci USA 1998, 95:3644-3649.
83. Aprikian A.G., Cordon-Cardo C., Fair W.R., Reuter V.E. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer 1993, 71:3952-3965.
84. Hirano D., Okada Y., Minei S., Takimoto Y., Nemoto N. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 2004, 45:586-592. discussion 92.
85. Komiya A., Suzuki H., Imamoto T., Kamiya N., Nihei N., Naya Y., et al. Neuroendocrine differentiation in the progression of prostate cancer. Int J Urol 2009, 16:37-44.
86. Rocchi P., Boudouresque F., Zamora A.J., Muracciole X., Lechevallier E., Martin P.M., et al. Expression of adrenomedullin and peptide amidation activity in human prostate cancer and in human prostate cancer cell lines. Cancer Res 2001, 61:1196-1206.
87. Jin R.J., Wang Y., Masumori N., Ishii K., Tsukamoto T., Shappell S.B., et al. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Cancer Res 2004, 64:5489-5495.
88. Beltran H., Rickman D.S., Park K., Chae S.S., Sboner A., MacDonald T.Y., et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 2011, 1:487-495.
89. Lin D., Wyatt A.W., Xue H., Wang Y., Dong X., Haegert A., et al. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res 2014, 74:1272-1283.
90. Colombel M., Symmans F., Gil S., O'Toole K.M., Chopin D., Benson M., et al. Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am J Pathol 1993, 143:390-400.
91. Gleave M.E., Miayake H., Goldie J., Nelson C., Tolcher A. Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides. Urology 1999, 54:36-46.
92. McDonnell T.J., Troncoso P., Brisbay S.M., Logothetis C., Chung L.W., Hsieh J.T., et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992, 52:6940-6944.
93. July L.V., Akbari M., Zellweger T., Jones E.C., Goldenberg S.L., Gleave M.E. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 2002, 50:179-188.
94. Rocchi P., Beraldi E., Ettinger S., Fazli L., Vessella R.L., Nelson C., et al. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res 2005, 65:11083-11093.
95. Rocchi P., So A., Kojima S., Signaevsky M., Beraldi E., Fazli L., et al. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 2004, 64:6595-6602.
96. Giusiano S., Baylot V., Andrieu C., Fazli L., Gleave M., Iovanna J.L., et al. TP53INP1 as new therapeutic target in castration-resistant prostate cancer. Prostate 2012, 72:1286-1294.
97. Acunzo J., Andrieu C., Baylot V., So A., Rocchi P. Hsp27 as a therapeutic target in cancers. Curr Drug Targets 2014, 15:423-431.
98. Katsogiannou M., Andrieu C., Baylot V., Baudot A., Dusetti N.J., Gayet O., et al. The functional landscape of Hsp27 reveals new cellular processes such as DNA repair and alternative splicing and proposes novel anticancer targets. Mol Cell Proteomics 2014, 13:3585-3601.
99. Baylot V., Katsogiannou M., Andrieu C., Taieb D., Acunzo J., Giusiano S., et al. Targeting TCTP as a new therapeutic strategy in castration-resistant prostate cancer. Mol Ther 2012, 20:2244-2256.
100. Acunzo J., Baylot V., So A., Rocchi P. TCTP as therapeutic target in cancers. Cancer Treat Rev 2014, 40:760-769.
101. Andrieu C., Taieb D., Baylot V., Ettinger S., Soubeyran P., De-Thonel A., et al. Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E. Oncogene 2010, 29:1883-1896.
102. Suzuki H., Freije D., Nusskern D.R., Okami K., Cairns P., Sidransky D., et al. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 1998, 58:204-209.
103. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275:1943-1947.
104. Guertin D.A., Stevens D.M., Saitoh M., Kinkel S., Crosby K., Sheen J.H., et al. MTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 2009, 15:148-159.
105. Sarker D., Reid A.H., Yap T.A., de Bono J.S. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 2009, 15:4799-4805.
106. Graff J.R., Konicek B.W., McNulty A.M., Wang Z., Houck K., Allen S., et al. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 2000, 275:24500-24505.
107. Li P., Lee H., Guo S., Unterman T.G., Jenster G., Bai W. AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR. Mol Cell Biol 2003, 23:104-118.
108. Medema R.H., Kops G.J., Bos J.L., Burgering B.M. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 2000, 404:782-787.
109. Liu P., Li S., Gan L., Kao T.P., Huang H. A transcription-independent function of FOXO1 in inhibition of androgen-independent activation of the androgen receptor in prostate cancer cells. Cancer Res 2008, 68:10290-10299.
110. Eastham J.A., Hall S.J., Sehgal I., Wang J., Timme T.L., Yang G., et al. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 1995, 55:5151-5155.
111. Eastham J.A., Stapleton A.M., Gousse A.E., Timme T.L., Yang G., Slawin K.M., et al. Association of p53 mutations with metastatic prostate cancer. Clin Cancer Res 1995, 1:1111-1118.
112. Navone N.M., Labate M.E., Troncoso P., Pisters L.L., Conti C.J., von Eschenbach A.C., et al. P53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J Urol 1999, 161:304-308.
113. Burchardt M., Burchardt T., Shabsigh A., Ghafar M., Chen M.W., Anastasiadis A., et al. Reduction of wild type p53 function confers a hormone resistant phenotype on LNCaP prostate cancer cells. Prostate 2001, 48:225-230.
114. Cronauer M.V., Schulz W.A., Burchardt T., Ackermann R., Burchardt M. Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines. Oncogene 2004, 23:3541-3549.
115. Guseva N.V., Rokhlin O.W., Glover R.A., Cohen M.B. P53 and the proteasome regulate androgen receptor activity. Cancer Biol Ther 2012, 13:553-558.
116. Baylot V., Katsogiannou M., Andrieu C., Taieb D., Acunzo J., Giusiano S., et al. Targeting TCTP as a new therapeutic strategy in castration-resistant prostate. Cancer Mol Ther 2012.
117. Grasso C.S., Wu Y.M., Robinson D.R., Cao X., Dhanasekaran S.M., Khan A.P., et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012, 487:239-243.
118. Coppola V., De Maria R., Bonci D. MicroRNAs and prostate cancer. Endocr Relat Cancer 2010, 17. F1-17.
119. Maugeri-Sacca M., Coppola V., Bonci D., De Maria R. MicroRNAs and prostate cancer: from preclinical research to translational oncology. Cancer J 2012, 18:253-261.
120. ChunJiao S., Huan C., ChaoYang X., GuoMei R. Uncovering the roles of miRNAs and their relationship with androgen receptor in prostate cancer. IUBMB Life 2014, 66:379-386.
121. Mercatelli N., Coppola V., Bonci D., Miele F., Costantini A., Guadagnoli M., et al. The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PLoS ONE 2008, 3:e4029.
122. Galardi S., Mercatelli N., Giorda E., Massalini S., Frajese G.V., Ciafre S.A., et al. MiR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem 2007, 282:23716-23724.
123. Yun H., Lee M., Kim S.S., Ha J. Glucose deprivation increases mRNA stability of vascular endothelial growth factor through activation of AMP-activated protein kinase in DU145 prostate carcinoma. J Biol Chem 2005, 280:9963-9972.
124. He L., He X., Lim L.P., de Stanchina E., Xuan Z., Liang Y., et al. A microRNA component of the p53 tumour suppressor network. Nature 2007, 447:1130-1134.
125. Bommer G.T., Gerin I., Feng Y., Kaczorowski A.J., Kuick R., Love R.E., et al. P53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 2007, 17:1298-1307.
126. Chang T.C., Wentzel E.A., Kent O.A., Ramachandran K., Mullendore M., Lee K.H., et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007, 26:745-752.
127. Liu C., Kelnar K., Liu B., Chen X., Calhoun-Davis T., Li H., et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011, 17:211-215.
128. Jones P.A., Gonzalgo M.L., Tsutsumi M., Bender C.M. DNA methylation in bladder cancer. Eur Urol 1998, 33(Suppl. 4):7-8.
129. Chin S.P., Dickinson J.L., Holloway A.F. Epigenetic regulation of prostate cancer. Clin Epigenetics 2011, 2:151-169.
130. Cairns P., Okami K., Halachmi S., Halachmi N., Esteller M., Herman J.G., et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 1997, 57:4997-5000.
131. Suzuki H., Ueda T., Ichikawa T., Ito H. Androgen receptor involvement in the progression of prostate cancer. Endocr Relat Cancer 2003, 10:209-216.
132. Friedlander T.W., Roy R., Tomlins S.A., Ngo V.T., Kobayashi Y., Azameera A., et al. Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. Cancer Res 2012, 72:616-625.
133. Germann S., Gratadou L., Dutertre M., Auboeuf D. Splicing programs and cancer. J Nucleic Acids 2012, 2012:269570.
134. Matlin A.J., Moore M.J. Spliceosome assembly and composition. Adv Exp Med Biol 2007, 623:14-35.
135. Sette C. Alternative splicing programs in prostate cancer. Int J Cell Biol 2013, 2013:458727.
136. Dehm S.M., Schmidt L.J., Heemers H.V., Vessella R.L., Tindall D.J. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008, 68:5469-5477.
137. Zhang C., Li H.R., Fan J.B., Wang-Rodriguez J., Downs T., Fu X.D., et al. Profiling alternatively spliced mRNA isoforms for prostate cancer classification. BMC Bioinformatics 2006, 7:202.
138. Lapuk A.V., Volik S.V., Wang Y., Collins C.C. The role of mRNA splicing in prostate cancer. Asian J Androl 2014, 16:515-521.
139. Pedrotti S., Bielli P., Paronetto M.P., Ciccosanti F., Fimia G.M., Stamm S., et al. The splicing regulator Sam68 binds to a novel exonic splicing silencer and functions in SMN2 alternative splicing in spinal muscular atrophy. EMBO J 2010, 29:1235-1247.
140. Bonnal S., Vigevani L., Valcarcel J. The spliceosome as a target of novel antitumour drugs. Nat Rev Drug Discov 2012, 11:847-859.
141. Blair C.A., Zi X. Potential molecular targeting of splice variants for cancer treatment. Indian J Exp Biol 2011, 49:836-839.
142. Kannan K., Wang L., Wang J., Ittmann M.M., Li W., Yen L. Recurrent chimeric RNAs enriched in human prostate cancer identified by deep sequencing. Proc Natl Acad Sci USA 2011, 108:9172-9177.
143. Teles Alves I., Hartjes T., McClellan E., Hiltemann S., Bottcher R., Dits N., et al. Next-generation sequencing reveals novel rare fusion events with functional implication in prostate cancer. Oncogene 2014.
144. Smit F.P., Salagierski M., Jannink S., Schalken J.A. High-resolution ERG-expression profiling on GeneChip exon 1.0 ST arrays in primary and castration-resistant prostate cancer. BJU Int 2013, 111:836-842.
145. Sowalsky A.G., Xia Z., Wang L., Zhao H., Chen S., Bubley G.J., et al. Whole transcriptome sequencing reveals extensive unspliced mRNA in metastatic castration-resistant prostate cancer. Mol Cancer Res 2014.
146. Kumar-Sinha C., Tomlins S.A., Chinnaiyan A.M. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008, 8:497-511.
147. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.W., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-648.
148. Hermans K.G., Boormans J.L., Gasi D., van Leenders G.J., Jenster G., Verhagen P.C., et al. Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer. Clin Cancer Res 2009, 15:6398-6403.
149. Hollenhorst P.C., Paul L., Ferris M.W., Graves B.J. The ETS gene ETV4 is required for anchorage-independent growth and a cell proliferation gene expression program in PC3 prostate cells. Genes Cancer 2011, 1:1044-1052.
150. Perner S., Demichelis F., Beroukhim R., Schmidt F.H., Mosquera J.M., Setlur S., et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006, 66:8337-8341.
151. Park K., Tomlins S.A., Mudaliar K.M., Chiu Y.L., Esgueva R., Mehra R., et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 2010, 12:590-598.
152. van Leenders G.J., Boormans J.L., Vissers C.J., Hoogland A.M., Bressers A.A., Furusato B., et al. Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice. Mod Pathol 2011, 24:1128-1138.
153. Demichelis F., Fall K., Perner S., Andren O., Schmidt F., Setlur S.R., et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007, 26:4596-4599.
154. Rickman D.S., Soong T.D., Moss B., Mosquera J.M., Dlabal J., Terry S., et al. Oncogene-mediated alterations in chromatin conformation. Proc Natl Acad Sci USA 2012, 109:9083-9088.
155. Esgueva R., Perner S., J LaFargue C., Scheble V., Stephan C., Lein M., et al. Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Mod Pathol 2010, 23:539-546.
156. Mani R.S., Tomlins S.A., Callahan K., Ghosh A., Nyati M.K., Varambally S., et al. Induced chromosomal proximity and gene fusions in prostate cancer. Science 2009, 326:1230.
157. Zhang Y., Gong M., Yuan H., Park H.G., Frierson H.F., Li H. Chimeric transcript generated by cis-splicing of adjacent genes regulates prostate cancer cell proliferation. Cancer Discov 2012, 2:598-607.
158. Rickman D.S., Pflueger D., Moss B., VanDoren V.E., Chen C.X., de la Taille A., et al. SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. Cancer Res 2009, 69:2734-2738.
159. Mehra R., Tomlins S.A., Yu J., Cao X., Wang L., Menon A., et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 2008, 68:3584-3590.
160. Gsponer J.R., Braun M., Scheble V.J., Zellweger T., Bachmann A., Perner S., et al. ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2014, 17:126-131.
161. Casey O.M., Fang L., Hynes P.G., Abou-Kheir W.G., Martin P.L., Tillman H.S., et al. TMPRSS2-driven ERG expression in vivo increases self-renewal and maintains expression in a castration resistant subpopulation. PLoS ONE 2012, 7:e41668.
162. Iljin K., Wolf M., Edgren H., Gupta S., Kilpinen S., Skotheim R.I., et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res 2006, 66:10242-10246.
163. Boormans J.L., Korsten H., Ziel-van der Made A.J., van Leenders G.J., de Vos C.V., Jenster G., et al. Identification of TDRD1 as a direct target gene of ERG in primary prostate cancer. Int J Cancer 2013, 133:335-345.
164. Brase J.C., Johannes M., Mannsperger H., Falth M., Metzger J., Kacprzyk L.A., et al. TMPRSS2-ERG-specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-beta signaling. BMC Cancer 2011, 11:507.
165. Taylor B.S., Schultz N., Hieronymus H., Gopalan A., Xiao Y., Carver B.S., et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18:11-22.
166. Burdova A., Bouchal J., Tavandzis S., Kolar Z. TMPRSS2-ERG gene fusion in prostate cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2014, 158:502-510.
167. Tangutoori S., Baldwin P., Sridhar S. PARP inhibitors: a new era of targeted therapy. Maturitas 2015.